Kornimate/medical-research-clean huggingface dataset:
68ga-alfatideii for the differential diagnosis of of lung cancer and lung tuberculosis by pet/ct

Conditions: Lung Cancer; Lung Tuberculosis

Summary: comparison of 68ga-alfatideii and 18f-fdg in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.


Eligibility criteria:
inclusion criteria: * must be able to provide a written informed consent * males and females, ≥18 years old. * the definite diagnosis of lung cancer was established by pre-operational bronchoscopic or puncture biopsy or the definite diagnosis of lung tuberculomas was established on the basis of positive sputum culture examinations and confirmed by follow-up. * without any treatment or resection surgury. * all the biopsies are done at least 10 days before pet/ct scans. * evaluation of cardiac function. exclusion criteria: * females planning to bear a child recently or with childbearing potential； * known severe allergy or hypersensitivity to iv radiographic contrast； * inability to lie still for the entire imaging time because of cough, pain, etc. * inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. * concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.

Keywords: 68ga alfatide ii rgd αvβ3 pet/ct
pacemaker-related tricuspid regurgitation progression and long-term outcomes

Conditions: Tricuspid Regurgitation; Pacemaker

Summary: tricuspid regurgitation (tr) is a common complication following cardiac implantable electronic device (cied) implantation, with severe tr being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. with technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods. this study aims to evaluate predictors of adverse outcomes and tr progression in cied recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.

this retrospective study analyzed patients undergoing pacemaker implantation from january 2015 to march 2025, stratified by pacing modality (right ventricular/conduction system/biventricular pacing) and tr progression (worsened \[≥1-grade increase\] vs non-worsened tr). the protocol included: (1) 3d echocardiographic assessment of tr mechanisms, (2) quantitative fluoroscopic analysis of lead parameters (tension, mobility, angulation), (3) multivariable regression evaluating pacing modes and tr progression on clinical outcomes, and (4) documentation of device-related complications (lead dislodgement/infection) and heart failure rehospitalization.

Eligibility criteria:
inclusion criteria: 1. adult patients 2. patients with an implantable electronic heart device (cieds) 3. the patient underwent pacemaker implantation at qianfoshan hospital between 2015 and 2025 exclusion criteria: 1. patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation 2. patients with severe valvular heart disease, congenital heart disease, or arrhythmias 3. patients with single-chamber pacemakers or poor images
auditory sensory attenuation in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the goal of this observational cross-sectional study is to test the sensory attenuation effect with auditory stimuli comparing women affected by anorexia nervosa and healthy-weight women. specifically, the study aims to test whether the sensory attenuation effect (i.e., the perceived loudness of a self-generated sound is weaker than when another person produces the same sound): i) is observed in anorexia nervosa ii) it can be modulated in interactive action contexts, as was previously observed in healthy participants. participants will compare the loudness of target sound with a comparison tone, which can be prompt by the participant by pressing a button on their own will (i.e., individual context) or upon the experimenter\&#39;s signal (i.e., interactive context); externally-generated sounds are produced in the opposite way.

the perceived loudness of a self-generated sound is generally weaker than when another person produces the same sound. this effect is known as sensory attenuation, and it is considered a proof of sense of agency (i.e., it relies on the anticipation of the sensory-motor effects of one\&#39;s intentional action). recently, it was suggested that this effect is enhanced in interactive action contexts in healthy individuals, meaning that sounds are produced as a consequence of cooperation between individuals. participants will compare the loudness of target sound with a comparison tone, which could be generated in 4 different conditions: i) participants press a button ii) the experimenter press the button iii) participants press the button upon the experimenter\&#39;s signal (i.e., who touch the participants\&#39; arm) iv) the experimenter presses the button upon the participants\&#39; signal (i.e., who touch the experimenter\&#39;s arm). however, it is not clear whether the same effect of cooperation can be observed also when individuals experience difficulties in social interactions and relationships. to this purpose, the study compared the sensory attenuation effect for auditory stimuli in a traditional (i.e., individual) and interactive context, comparing women affected by anorexia nervosa with healthy-weight women. indeed, relational difficulties and social withdrawal characterized this clinical condition.

Eligibility criteria:
inclusion criteria: * diagnosis of anorexia nervosa according to the dsm-v classification (experimental group) * bmi ranged between 19 - 25 kg/m2 (controls) * handedness: right exclusion criteria: * history of eating disorders (controls) * major psychiatric conditions (e.g., psychosis, personality disorders) * developmental disorders (e.g., autism spectrum disorders) * neurological or brain injuries disorders * motor impairments

Keywords: anorexia nervosa sensory attenuation anhedonia cognitive empathy interpersonal difficulties
lung cancer screening navigation for homeless people

Conditions: Lung Cancer; Tobacco Use; Homelessness

Summary: the investigators will conduct a pragmatic clinical trial to test the effect of patient navigation on lung cancer screening (lcs) low-dose computed tomography (ldct) completion among boston health care for the homeless program (bhchp) patients at increased risk for lung cancer. patient navigation is a strategy for guiding individuals through complex health systems, and the investigators hypothesize that this may be a promising approach for helping homeless-experienced people overcome their unique barriers to obtaining lcs. the investigators will aim to recruit 300 people to participate in this research study; 100 will be randomly assigned to arm 1 (usual care) and 200 will be randomly assigned to arm 2 (patient navigation). randomization of participants will be stratified by smoking status, housing status, clinical site, and whether they have previously discussed lcs with their primary care provider (pcp) to ensure balance between study groups on these variables. people assigned to the usual care arm will be referred back to their pcp for further management. people assigned to the patient navigation arm will be given the chance to work with a lcs navigator. the navigator will assist participants and their pcps with all aspects of the lcs process in addition to offering brief tobacco counseling for current smokers. the primary aim of the trial is to determine-among homeless-experienced people who are eligible for lcs-the effect of patient navigation on 1) lcs ldct completion at 6 months post-enrollment and 2) lcs ldct completion at 6 months with diagnostic follow-up of abnormal results within 1 month of the recommended time frame. study outcomes will be assessed by examining participant health records. following the intervention, qualitative interviews will be conducted with 40 participants and 10 bhchp pcps to better understand how the lcs process unfolds in the setting of homelessness, the ways in which the navigator facilitated this process, and opportunities for improving the navigation intervention for future use.


Eligibility criteria:
inclusion criteria: * currently or formerly homeless * have a 30 pack-year smoking history and have smoked within the past 15 years * have a boston health care for the homeless (bhchp) primary care provider (pcp) * proficient in english, assessed with items asking about native language and self-reported comfort communicating in english among non-native speakers exclusion criteria: * prior chest computed tomography (ct) imaging in the past 12 months * personal history of lung cancer, or current presentation with symptoms concerning for lung cancer (e.g. hemoptysis or unexplained weight loss of \>15 lbs. in the past year) * pcp is the principal investigator * inability to provide informed consent, assessed with knowledge questions about the material presented during the informed consent process that individuals must correctly answer before providing informed consent to participate

Keywords: lung cancer screening tobacco use homeless persons smoking low-dose computed tomography
autologous tumor infiltrating lymphocyte injection for the treatment of advanced solid tumors

Conditions: Solid Tumor; Adult; GT316

Summary: this trial is a multicenter, single-arm, open design designed to evaluate the safety and tolerability of autologous tumor infiltrating lymphocyte injection in the treatment of patients with advanced solid tumors, as well as pharmacokinetic profiling and efficacy. the trial consists of two phases: dose-escalation and dose-expansion.


Eligibility criteria:
inclusion criteria: * 1.the patients (or legally authorized representative) patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (icf) approved by an institutional review board/independent ethics committee (irb/iec), must have the ability to understand the requirements of the study; * 2.must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor; * 3.at least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. the separated tissues ≥1.0cm\^3 (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. minimally invasive treatment where possible; exclusion criteria: * 1.patients with ≥3 untreated cns metastases at the time of screening (patients were included if they had ≤3 cns metastases with a maximum diameter of \<1 cm and no peritumor edema on brain imaging (mri or ct) and no evidence of progressive cns disease on brain imaging for at least 3 months after treatment) * 2.the patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\>10 mg/day of prednisone or equivalent hormone); * 3. arterial/venous thrombotic events within 3 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring; * 4.patients with refractory or intractable epilepsy, drug-uncontrolled pleural effusion, abdominal effusion, pericardial effusion, active gastrointestinal bleeding or contraindications to il-2; * 5. participate in other clinical trials within 4 weeks prior to screening, or planning to participate in this study and other clinical trials at the same； * 6. patients who have received allogeneic bone marrow transplantation or an organ allograft; * 7.patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, il-2, dimethyl sulfoxide (dmso), human serum albumin (hsa), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);
role of inhaled nitric oxide in vascular mechanics and right ventricular function

Conditions: Collapsed Lung; Hemodynamic Stability

Summary: the aim of this study is to evaluate the role of nitric oxide on pulmonary vasculature and right ventricular function in postoperative cardiac surgery patients.

this study will evaluate modifiable pathophysiological treatments for postoperative pulmonary hypertension and right ventricular dysfunction. one pharmacological, inhaled nitric oxide, and one non-pharmacological, the ola strategy combining lung recruitment and stabilization with individually optimized positive end-expiratory pressure (peep) and the possible synergistic effects of both interventions on right ventricular performance. apart from acting specifically on the pathophysiological mechanisms described, the combination of an ola strategy and ino may be particularly beneficial, as modification of pulmonary status by ola may, in theory, enhance the effects of ino by significantly increasing gas exchange area and thus alveolar ventilation. a number of closely related physiological variables will also be studied to better characterize the effects of both strategies and their combination. this may help to better establish the indication for ino in cardiac surgery patients and improve our understanding of mechanisms that are also present in ards patients, albeit on a different scale. this is a prospective randomized controlled physiological prospective study to be performed in two hospitals. the intervention period is limited to the first 2 -3 hours postoperatively. a total of 54 patients will be recruited.

Eligibility criteria:
* age \> 18 years * under controlled mechanical ventilation in passive conditions * presence of postoperative lung collapse (confirmed by pulmonary echocardiography and air test) * preoperative left ventricular ejection fraction (lvef) ≥ 30%. * absence of hypovolemia: absence of "kissing" ventricles and/or collapsibility index of the superior vena cava \< 20%. * stable spontaneous heart rhythm * postoperative hemodynamic stability: * mean arterial pressure (map) ≥ 60 mmhg * central venous pressure (cvp) ≥ 10 mmhg * heart rate (hr) ≤ 100 bpm without tachyarrhythmias * lactic acid ≤ 3 mmol/l * single vasopressor treatment * norepinephrine dose ≤ 0.2 μg/kg/min, without an increase ≥ 15% in the last 30 -minutes. obtained informed consent
innovation in endobronchial sampling

Conditions: Diffuse Interstitial Lung Disease

Summary: evaluating an integrated diagnostic work-up of virtual navigation bronchoscopy (vnb), confocal laser endomicroscopy and micro computerized tomography (micro-ct) in the diagnostic path of pulmonary lesions in the non-oncological patient.

the region(s) of interest that has/have to be sampled, will be selected upfront. guided by the endobronchial pathway that is created by virtual bronchoscopy, the flexible bronchoscope will be navigated to the regions of interest and an optical biopsy of the region will be obtained using pcle. one biopsy sample will be processed in the endoscopy suite to be able to prepare it for micro-ct analysis.

Eligibility criteria:
inclusion criteria: * presence of diffuse pulmonary disease necessitating bronchoscopic evaluation. * informed consent available * age \> 18 * fvc \> 50%pred * dlco \> 35%pred * pao2 \> 55 mmhg, pco2 \< 45 mmhg (ambient air) * no exclusion criteria exclusion criteria: * age \> 75 * systolic arterial pressure in the pulmonary artery : paps \>40mmhg * platelet count \<100000/µl * inr \> 1.4 * bmi \>30 * diffuse bullous lung disease * active anti-platelet or anticoagulant treatment * active heart failure or unstable coronary heart disease
diffusion weighted magnetic resonance imaging for preoperative staging in gastric adenocarcinoma patients

Conditions: Gastric Adenocarcinoma

Summary: preoperative staging for gastric adenocarcinoma is an important procedure to detect advanced disease states for the patients in which the surgery may be unnecessary to perform. although there are many imaging techniques for this purpose, sensitivity and specificity of these techniques still remains to be low.preoperative detection of peritoneal carcinomatosis and involvement of lymph nodes beyond d2 may prevent surgical procedures. removal of the determined lymph nodes according to the type of the surgery is the accepted surgical method. however, accurate determination of malignant lymph nodes may prevent dissection of some groups of the lymph nodes. these findings may cause a new definition of gastric lymph node dissection.

1. proven endoscopic diagnosis of gastric adenocarcinoma 2. for staging purposes, computed tomography for all patients 3. evaluation of benign and malignant lymph nodes according to computed tomography findings and mapping of the lymph nodes 4. to state precisely resectable patients according to computed tomography and anesthetic evaluation 5. evaluation of benign and malignant lymph nodes according to diffusion weighted magnetic resonance imaging findings and mapping of the lymph nodes 6. standard gastrectomy and d2 lymph node dissection 7. mapping of the lymph nodes after taking the specimen out 8. histopathological diagnosis of the lymph nodes and mapping 9. comparison of the results taken from computed tomography, diffusion weighted magnetic resonance imaging and histopathological analysis

Eligibility criteria:
inclusion criteria: * gastric adenocarcinoma proven by endoscopic biopsy; * application of both computed tomography and diffusion weighted magnetic resonance imaging; * standard gastrectomy and a d2 lymph node dissection; * desire to attend the study protocol exclusion criteria: * preoperative neoadjuvant therapy; * metastatic disease; * undesired reaction to attend the study protocol

Keywords: diffusion weighted magnetic resonance imaging surgery histopathology
optimizing current and electrode montage for transcranial direct current stimulation in stroke patients

Conditions: Stroke

Summary: the purpose of this study is to determine the optimal transcranial direct current stimulation (tdcs) amplitude and electrode montage that is both safe and efficacious

transcranial direct current stimulation (tdcs) is a non-invasive brain stimulation technique that can modulate cortical excitability of targeted brain regions. various studies have investigated tdcs use in stroke patients with motor impairments (cumulatively about 200 cases). although these studies are mostly "proof of concept" with small sample size, they do suggest that tdcs may improve motor function. however these two questions have not been addressed systematically: 1. what is the optimal current for stroke patients? 2. what is the optimal tdcs electrode montage for stimulation? this proposal lays the scientific foundation for systematic application of tdcs in stroke recovery research by progressively increasing tdcs currents and montages that are both safe and efficacious in population with stroke.

Eligibility criteria:
inclusion criteria: * 18-80 years old with a first-ever ischemic stroke that occurred at least 6 months ago; * finished rehabilitation therapy(including inpatient or outpatient physical therapy (pt) / occupational therapy (ot) / speech therapy (sp)) at least one month ago; * unilateral limb weakness with fugl meyer-upper extremity scale score less than 56 (out of 66); * motor evoked potentials (mep) is inducible on abductor pollicis brevis (apb) muscle on the affected side by tms. exclusion criteria: * primary intracerebral hematoma, or subarachnoid hemorrhage, * bihemispheric ischemic strokes; * history of prior stroke or old infarct demonstrated on the ct or mri or documented in medical records; * other concomitant neurological disorders affecting upper extremity motor function; * documented history of dementia before or after stroke; * documented history of uncontrolled depression or psychiatric disorder either before or after stroke which could affect their ability to participate in the experiment; * uncontrolled hypertension despite treatment, specifically systolic blood pressure (sbp)/ diastolic blood pressure (dbp) \>= 180/100 mmhg at baseline; * presence of any mri/tdcs/tms risk factors: a) an electrically, magnetically or mechanically activated metal or nonmetal implant including cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system; b) non-fixed metal in any part of the body, including a previous metallic injury to eye; c) pregnancy, since the effect of tdcs on the fetus is unknown; d) history of seizure disorder or post-stroke seizure; e) preexisting scalp lesion, bone defect or hemicraniectomy.

Keywords: transcranial direct current stimulation tdcs
s-1, irinotecan, and oxaliplatin in locally-advanced pancreatic cancer

Conditions: Pancreatic Ductal Adenocarcinoma

Summary: this phase ii clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the simon's two-stage optimum design. after 4 cycles of sirox regimen, patients will proceed to curative resection.

this phase ii clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the simon's two-stage optimum design. after 4 cycles of sirox regimen, patients will proceed to curative resection. the primary endpoint of this study is resection rate after neoadjuvant chemotherapy. the first stage will enroll 18 patients. we will go into the second stage if at least 2 patients in stage i become resectable after treatment. there will be at most 35 patients enrolled. based on this trial, we anticipate that the sirox regimen has comparable response rate and resection rate but lower toxicities comparing to folfirinox.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically proven pancreatic adenocarcinoma 2. newly diagnosed, unresectable, locally-advanced pancreatic cancer 3. no potential of r0 resection at diagnosis 4. presence of measurable pancreatic lesion, which must meet the criteria of being ≥ 10 mm in at least one dimension by conventional ct/mri 5. age between 20 and 79 years at registration 6. ecog performance status (ps) of 0 or 1 7. adequate major organ functions 8. ability to take the oral study medication (s-1) 9. no clinically significant abnormal ecg findings within 28 days (4 weeks) prior to registration 10. voluntarily signed the written informed consent form exclusion criteria: 1. pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to registration 2. presence of diarrhea ≥ ctcae v.4.03 grade 2 3. concomitant active infection 4. significant co-morbid medical conditions, including, but not limited to , heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes 5. moderate or severe ascites or pleural effusion that requires drainage 6. prior or concurrent malignancies within the last 3 years, with the exception of carcinoma in situ of the cervix, or basal type skin cancer 7. concomitant treatment with flucytosine, phenytoin or warfarin 8. peripheral neuropathy grade of 2 or higher 9. known gilbert syndrome or homozygosity for ugt1a1 promoter ta repeats prone to high risk of drug toxicity (screening of ugt1a1 genotype will not performed routinely before study) 10. pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. patients of childbearing age should have effective contraception for both the patient and his or her partners during the study period 11. severe mental disorder 12. judged ineligible by physician for participation in the study due to safety concern